About: Early Safety Indicators of COVID-19 ConvalescentPlasma in 5,000 Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Early Safety Indicators of COVID-19 ConvalescentPlasma in 5,000 Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Early Safety Indicators of COVID-19 ConvalescentPlasma in 5,000 Patients
Creator	Casadevall, Arturo Wright, R Bauer, Philippe Fairweather, Delisa Paneth, Nigel Andersen, Kylie Baker, Sarah Blair, Janis Bruno, Katelyn Buras, Matthew Carter, Rickey Clayburn, Andrew Dennis, Joshua Herasevich, Vitaly Hodge, David Johnson, Patrick Joyner, Michael Klassen, Stephen Klompas, Allan Kunze, Katie Larson, Kathryn Lesser, Elizabeth Rea, Robert Regimbal, Riley Ripoll, Juan Senefeld, Jonathon Shepherd, John Spiegel, Matthew Stubbs, James Van Buskirk, Camille Vogt, Matthew Whelan, Emily Wiggins, Chad Winters, Jeffrey
Source	MedRxiv; Medline
abstract	Background: Convalescent plasma is the only antibody based therapy currently available for COVID-19 patients. It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma has not yet been shown to be safe as a treatment for COVID-19. Methods: Thus, we analyzed key safety metrics after transfusion of ABO-compatible human COVID-19 convalescent plasma in 5,000 hospitalized adults with severe or life threatening COVID-19, with 66% in the intensive care unit, as part of the US FDA Expanded Access Program for COVID-19 convalescent plasma. Results: The incidence of all serious adverse events (SAEs) in the first four hours after transfusion was <1%, including mortality rate (0.3%). Of the 36 reported SAEs, there were 25 reported incidences of related SAEs, including mortality (n=4), transfusion-associated circulatory overload (TACO; n=7), transfusion-related acute lung injury (TRALI; n=11), and severe allergic transfusion reactions (n=3). However, only 2 (of 36) SAEs were judged as definitely related to the convalescent plasma transfusion by the treating physician. The seven-day mortality rate was 14.9%. Conclusion: Given the deadly nature of COVID-19 and the large population of critically-ill patients included in these analyses, the mortality rate does not appear excessive. These early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19.
has issue date	2020-05-14(xsd:dateTime)
bibo:doi	10.1101/2020.05.12.20099879
bibo:pmid	32511566
has license	medrxiv
sha1sum (hex)	74326ec1e920f6b74c95dafcf10475396f9dba48
schema:url	https://doi.org/10.1101/2020.05.12.20099879
resource representing a document's title	Early Safety Indicators of COVID-19 ConvalescentPlasma in 5,000 Patients
has PubMed identifier	32511566
schema:publication	medRxiv : the preprint server for health sciences
resource representing a document's body	covid:74326ec1e920f6b74c95dafcf10475396f9dba48#body_text
is schema:about of	named entity 'Thus' named entity 'incidence' named entity 'PROGRAM' named entity 'BASED' named entity 'ABO' named entity 'ADULTS' covid:arg/74326ec1e920f6b74c95dafcf10475396f9dba48 named entity 'robust' named entity 'SAEs' named entity 'transfusion' named entity 'incidences' named entity 'intensive care unit' named entity 'patients' named entity 'plasma' named entity 'US FDA' named entity 'Patients' named entity 'COVID-19' named entity 'transfusion' named entity 'transfusion' named entity 'intensive care unit' named entity 'COVID' named entity 'mortality rate' named entity 'plasma' named entity 'Wuhan' named entity 'toxicity' named entity 'EAP' named entity 'pulmonary complications' named entity 'TRALI' named entity 'respiratory frequency' named entity 'ADE' named entity 'plasma' named entity 'convalescent plasma' named entity 'fatality rate' named entity 'epidemic' named entity 'Transfusion-related acute lung injury' named entity 'COVID-19 outbreak' named entity 'SAEs' named entity '14,000' named entity 'COVID' named entity 'peer review' named entity 'case fatality rate' named entity 'risk factors' named entity 'SARS-CoV-1' named entity 'peer review' named entity 'medRxiv' named entity 'critically ill' named entity 'EAP' named entity 'COVID-19' named entity 'FDA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software